Supernus Pharmaceuticals (NASDAQ:SUPN) Posts Quarterly Earnings Results, Beats Expectations By $0.15 EPS

Supernus Pharmaceuticals (NASDAQ:SUPN - Get Free Report) issued its earnings results on Tuesday. The specialty pharmaceutical company reported $0.61 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.46 by $0.15, Zacks reports. Supernus Pharmaceuticals had a return on equity of 7.79% and a net margin of 9.16%. The company had revenue of $174.16 million for the quarter, compared to analysts' expectations of $155.25 million. Supernus Pharmaceuticals updated its FY 2025 guidance to EPS.

Supernus Pharmaceuticals Stock Up 0.9 %

NASDAQ SUPN traded up $0.30 on Friday, reaching $32.06. The company had a trading volume of 675,673 shares, compared to its average volume of 495,573. The stock has a market capitalization of $1.77 billion, a P/E ratio of 29.96 and a beta of 0.90. The company's fifty day moving average is $37.12 and its 200 day moving average is $35.34. Supernus Pharmaceuticals has a 52-week low of $25.53 and a 52-week high of $40.28.

Wall Street Analyst Weigh In

A number of brokerages recently issued reports on SUPN. StockNews.com cut Supernus Pharmaceuticals from a "strong-buy" rating to a "buy" rating in a report on Thursday. Cantor Fitzgerald reiterated a "neutral" rating and issued a $36.00 target price on shares of Supernus Pharmaceuticals in a report on Wednesday.

Remove Ads

Insider Activity at Supernus Pharmaceuticals

In related news, VP Padmanabh P. Bhatt sold 9,477 shares of the stock in a transaction on Tuesday, February 4th. The stock was sold at an average price of $39.70, for a total value of $376,236.90. Following the completion of the sale, the vice president now directly owns 10,149 shares of the company's stock, valued at approximately $402,915.30. This represents a 48.29 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, SVP Jonathan Rubin sold 927 shares of the stock in a transaction on Friday, February 21st. The shares were sold at an average price of $39.15, for a total value of $36,292.05. Following the completion of the sale, the senior vice president now directly owns 7,853 shares of the company's stock, valued at $307,444.95. The trade was a 10.56 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 11,104 shares of company stock valued at $440,263. 9.30% of the stock is owned by insiders.

About Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.